In patients already prescribed glucose-lowering drugs based on metabolic conditions, concurrent initiation of SGLT-2 inhibitors is emerging as a feasible strategy to evaluate their potential effects on AF incidence and burden [19]. This evidence concerns the gene SLC5A2 and atrial fibrillation.